OHKI HEALTHCARE HOLDINGS CO.,LTD.
3417・Standard Market・Wholesale Trade
Business
Ohki Healthcare Holdings is a company listed on the TSE Standard Market, established in 2015 as a holding company for Ohki Co., Ltd. Its predecessor traces back to "Ohki Gozoen Honpo," founded in 1658, making it a historic corporate group. Centered on its main subsidiary Ohki Co., Ltd., the company operates an intermediate distribution (wholesale) business covering healthcare categories such as pharmaceuticals, health foods, cosmetics, sanitary products, and daily sundries. It partners with retail companies, primarily drugstores, and advocates a "demand-creation" model that surfaces consumers' latent needs. The group consists of 8 consolidated subsidiaries and operates its business as a single segment.
Business Model
While maintaining the traditional intermediary distribution business model of purchasing products from manufacturers and wholesaling to retail companies, the company focuses on increasing the proportion of "distribution-exclusive products" handled and proposing unique categories in order to move away from mere price competition. Through collaboration with investees and business alliance partners, the company provides sales promotion support and in-store sales capability enhancement support, aiming to establish its position as an "only-one wholesaler" that is difficult for retail companies to replace. Revenue is mainly derived from the gross profit margin on product transactions (gross profit), with dividend income, among other items, also recorded as non-operating income.
Company Strengths
Revenue for FY2026 (ending March 2026) reached ¥360,358 million, expanding approximately 30% over four fiscal periods from ¥278,162 million in FY2022 (ended March 2022). The company possesses broad procurement capability spanning 8 categories including pharmaceuticals, health foods, cosmetics, and daily necessities, with total purchases reaching ¥346,247 million. As a specialized wholesaler focused on the healthcare category, it has built a stable supply system for retail companies.
The predecessor "Ohki Gozoen Honpo" was founded in 1658, giving Ohki Co., Ltd. a history spanning over 360 years. This long-term track record forms the foundation of trust relationships with both retail companies and manufacturers, enabling the company to build a network with like-minded partner companies. The securities report cites sales promotion support through collaboration with investees and business alliance partners as a concrete strength.
The company is pursuing a strategy of continuously increasing the sales composition ratio of distribution-exclusive products, aiming to establish distribution channel strength that does not depend on price competition. Its demand-creation model—surfacing latent demand through new category proposals and new product development support—represents a proprietary initiative that differentiates itself from simple price competition, providing retail companies with added value that is difficult to replicate.
ENVALITH's Perspective
Performance Trend
Revenue grew for five consecutive fiscal years, from ¥278,162 million in FY2022 (ended March 2022) to ¥360,358 million in FY2026 (ending March 2026). However, operating profit fell sharply from ¥2,768 million in FY2025 (ended March 2025) to ¥719 million in FY2026 (ending March 2026), with the operating margin declining from 0.8% to 0.2%. The decline in profit resulted from a combination of factors: revisions to trading terms and higher center fees stemming from consolidation among major retailers, delays in passing on product price increases, continued rises in labor and logistics costs, increased upfront investment in digitalization and systemization, one-time costs from the relocation of head office functions, and inventory disposal at a subsidiary. As an external factor, slowing healthcare demand due to the domestic inflationary trend also acted as a headwind.
Growth Strategy
As a demand-creation-type wholesaler, the company is advancing new category development, expansion of distribution-exclusive products, and digitalization
Continuing to develop and expand distribution-exclusive products in collaboration with manufacturers, building a product portfolio that can avoid price competition. Aiming to strengthen price negotiating power with major retailers and improve profit margins. In FY2026 (ending March 2026), the gross profit margin has declined, making it an urgent priority to realize the effects of increasing this product mix.
Continuing upfront investment in the digitalization of indirect operations, starting with the logistics division. Promoting business improvement not only within the company's group but also among distribution industry stakeholders. In FY2026 (ending March 2026), the burden of upfront investment has increased, becoming a short-term cost factor, but the company aims to realize mid-to-long-term cost reduction effects.
Deepening the demand-creation-type model that uncovers consumers' latent demand through sales promotion support and in-store sales strengthening support in collaboration with investees and business partners. Aiming to expand per-capita healthcare-related product consumption expenditure. Continuing to promote this as a differentiation strategy amid the external environment of declining total demand due to population decrease.
Responding to soaring raw material, materials, and transportation costs and procurement instability caused by turmoil in the Middle East situation, positioning stable product supply as the top priority issue. Uncertainty has increased to the point where the company has not disclosed its earnings forecast for FY2027 (ending March 2027), making the strengthening of supply chain management the most critical management issue.
Last updated: July 19, 2026